Contact
searchSearch
HMP Global

Diffuse Large B-Cell Lymphoma Topic Center

Featured Article

News
Early, Late DLBCL Relapse Linked With Distinct Evolutionary Dynamics
08/17/2023
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have...
08/17/2023
First Report Managed Care
News
Zanubrutinib Plus R-CHOP Effective for Non-GCB DLBCL With Extranodal Involvement
08/02/2023
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy...
08/02/2023
First Report Managed Care
News
Study Finds Low Rate of CAR T-cell Therapy in Older Adults With DLBCL
07/27/2023
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was...
07/27/2023
First Report Managed Care
News
CNS Prophylaxis Shows Limited Effectiveness in Preventing CNS Relapse in DLBCL
07/21/2023
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness,...
07/21/2023
First Report Managed Care
News
Prognosis Worse for Patients With DLBCL and Mental Health Disorders
07/20/2023
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse...
07/20/2023
First Report Managed Care
News
Epcoritamab Shows Durable Response in Relapsed/Refractory Large B-Cell Lymphoma
07/14/2023
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response...
07/14/2023
First Report Managed Care
News
Biosimilar Rituximab Compared to Originator Rituximab for Treatment of Patients With DLBCL
05/12/2023
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a...
05/12/2023
Oncology
From Oncology
Elizabeth Brem University of California Irvine
Videos
Analyzing Patient Selection and the Utility of CNS Prophylaxis for Patients With DLBCL
04/20/2023
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great...
04/20/2023
Oncology
From Oncology
Jennifer Amengual, MD, Columbia University
Videos
Choosing Treatment Options for Patients With R/R DLBCL Ineligible for CAR T-Cell Therapy
04/18/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
At the 2023 Great Debates &...
04/18/2023
Oncology
From Oncology
News
Anti-CD19 Monoclonal Antibodies for Treating Patients With R/R DLBCL
05/20/2022
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed...
05/20/2022
First Report Managed Care
News
Loncastuximab Tesirine Efficacious, Safe for Patients With R/R DLBCL
05/13/2022
Study authors assessed the efficacy of loncastuximab tesirine in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Study authors assessed the efficacy of loncastuximab tesirine in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Study authors assessed the...
05/13/2022
First Report Managed Care

Newsfeed

News
Early, Late DLBCL Relapse Linked With Distinct Evolutionary Dynamics
08/17/2023
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have...
08/17/2023
First Report Managed Care
News
Zanubrutinib Plus R-CHOP Effective for Non-GCB DLBCL With Extranodal Involvement
08/02/2023
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy...
08/02/2023
First Report Managed Care
News
Study Finds Low Rate of CAR T-cell Therapy in Older Adults With DLBCL
07/27/2023
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was...
07/27/2023
First Report Managed Care
News
CNS Prophylaxis Shows Limited Effectiveness in Preventing CNS Relapse in DLBCL
07/21/2023
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness,...
07/21/2023
First Report Managed Care
News
Prognosis Worse for Patients With DLBCL and Mental Health Disorders
07/20/2023
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse...
07/20/2023
First Report Managed Care
News
Epcoritamab Shows Durable Response in Relapsed/Refractory Large B-Cell Lymphoma
07/14/2023
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response...
07/14/2023
First Report Managed Care
News
Biosimilar Rituximab Compared to Originator Rituximab for Treatment of Patients With DLBCL
05/12/2023
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a...
05/12/2023
Oncology
News
Anti-CD19 Monoclonal Antibodies for Treating Patients With R/R DLBCL
05/20/2022
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed...
05/20/2022
First Report Managed Care
News
Loncastuximab Tesirine Efficacious, Safe for Patients With R/R DLBCL
05/13/2022
Study authors assessed the efficacy of loncastuximab tesirine in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Study authors assessed the efficacy of loncastuximab tesirine in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Study authors assessed the...
05/13/2022
First Report Managed Care
News
HRQoL Maintained or Improved With Treatment for Patients With R/R DLBCL
04/25/2022
An antibody-drug conjugate already shown to have antitumor activity and manageable toxicity also improved health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma, according to new findings. 
An antibody-drug conjugate already shown to have antitumor activity and manageable toxicity also improved health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma, according to new findings. 
An antibody-drug conjugate...
04/25/2022
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care
FRMC Volume 21, Issue 3

Current Issue

September 2024
Volume 21
Issue 3
Current Issue
Issue Archive

What's Trending?

News
Roche gets Europe OK for new Herceptin formulation
09/03/2013
09/03/2013
First Report Managed Care
News
Trump Backs Negotiating Drug Prices Under Medicare: White House
02/08/2017
In a recent briefing, it was revealed that President Donald Trump has showed his support in favor of drug pricing negotiations. 
In a recent briefing, it was revealed that President Donald Trump has showed his support in favor of drug pricing negotiations. 
In a recent briefing, it was...
02/08/2017
First Report Managed Care
Headshot of Adam Kittai, Ohio State University, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
CLL Research Update, Comparative Efficacy of Combination Treatments
12/14/2021
In part one of this podcast series, Adam Kittai, MD, hematologist and assistant professor of medicine, Ohio State University, provides an overview of current research being conducted on chronic lymphocytic leukemia and discusses the results...
In part one of this podcast series, Adam Kittai, MD, hematologist and assistant professor of medicine, Ohio State University, provides an overview of current research being conducted on chronic lymphocytic leukemia and discusses the results...
In part one of this podcast...
12/14/2021
First Report Managed Care
Preventable Hospital Readmissions among Medicare Beneficiaries
04/22/2013
Reducing preventable hospital readmissions is part of a federal strategy to create incentives to improve quality of care. In an effort to lower hospital readmission rates, the Centers for Medicare & Medicaid Services publicly reports...
Reducing preventable hospital readmissions is part of a federal strategy to create incentives to improve quality of care. In an effort to lower hospital readmission rates, the Centers for Medicare & Medicaid Services publicly reports...
Reducing preventable hospital...
04/22/2013
First Report Managed Care
News
State Efforts to Take Control of Medicaid Struggling
06/07/2011
06/07/2011
First Report Managed Care

Video Insights

Elizabeth Brem University of California Irvine
Videos
Analyzing Patient Selection and the Utility of CNS Prophylaxis for Patients With DLBCL
04/20/2023
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great...
04/20/2023
Oncology
Jennifer Amengual, MD, Columbia University
Videos
Choosing Treatment Options for Patients With R/R DLBCL Ineligible for CAR T-Cell Therapy
04/18/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
At the 2023 Great Debates &...
04/18/2023
Oncology
Videos
Bridging the Gaps in Prior Authorization: Challenges, Solutions, and Collaboration for Better Patient Care
11/13/2024
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief...
11/13/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Videos
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
09/25/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
09/25/2024
First Report Managed Care
Title Card
Videos
Addressing the Root Cause of a Common Ocular Condition: A Virtual Roundtable
09/04/2024
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on...
09/04/2024
First Report Managed Care
Jordan Bazinsky
Videos
Addressing Health Disparities and Promoting Equity: The Role of Advanced Imaging Solutions
08/15/2024
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky...
08/15/2024
First Report Managed Care
Farrukh Awan, MD
Videos
Promising Therapies and Clinical Trials for Chronic Lymphocytic Leukemia
08/14/2024
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights...
08/14/2024
Journal of Clinical Pathways
Hayward
Videos
Evolving Health Care Contact Centers Into Drivers of Value-Based Care
07/31/2024
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact...
07/31/2024
First Report Managed Care
Lucille Accetta Headshot
Videos
Enhancing Patient Medication Adherence: Insights and Strategies From Asembia 2024
06/11/2024
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health...
06/11/2024
First Report Managed Care
Melissa Andel, Principal, CommonHealth Solutions, LLC
Videos
Navigating the Impact of the Inflation Reduction Act: Implications for Payers, Patients, and Manufacturers
05/24/2024
Melissa Andel, Principal, CommonHealth Solutions, LLC
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the...
05/24/2024
First Report Managed Care

Subscribe to our eNewsletters!

First Report Managed Care Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use